Citations 41

Clinical efficacy of mychophenolate mofetil in treating lichen planopilaris

Dermatologic Therapy | June 8, 2022 | Volume: 35 | Issue: 8 | Pages: No page available

10.1111/dth.15625 | PMID 35674693

Demographic and clinical characteristics of hospitalized psoriasis patients

Journal of Cosmetic Dermatology | June 6, 2022 | Volume: 21 | Issue: 11 | Pages: 6476-6478

10.1111/jocd.15144 | PMID 35665588

New‐onset pemphigus foliaceus following SARS‐CoV‐2 infection and unmasking multiple sclerosis: A case report

Clinical Case Reports | June 3, 2022 | Volume: 10 | Issue: 6 | Pages: No page available

10.1002/ccr3.5910 | PMID 35662780

AbstractDevelopment of pemphigus foliaceus (PF) following SARS‐CoV‐2 infection has only been reported in one patient who had received Bamlanivimab and thus might be considered as a drug‐induced case of PF. Here, we reported the first case of PF arising solely after COVID infection without taking any culprit drug.
Dexamethasone or prednisone: Which one should be the corticosteroid of choice in patients with pemphigus vulgaris?

Dermatologic Therapy | April 14, 2022 | Volume: 35 | Issue: 7 | Pages: No page available

10.1111/dth.15511 | PMID 35419910

The role of SARS‐CoV‐2 infection and its vaccines in various types of hair loss

Dermatologic Therapy | March 10, 2022 | Volume: 35 | Issue: 6 | Pages: No page available

10.1111/dth.15433 | PMID 35266262

SARS‐CoV‐2 vaccination and practical points in psoriasis patients: A narrative review

Dermatologic Therapy | March 9, 2022 | Volume: 35 | Issue: 5 | Pages: No page available

10.1111/dth.15430 | PMID 35261123

Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic (VEXAS) syndrome: a presentation of two cases with dermatologic findings

International Journal of Dermatology | March 1, 2022 | Volume: 62 | Issue: 5 | Pages: No page available

10.1111/ijd.16132 | PMID 35230710

Atypical aphthous‐like oral lesions in a liver transplant patient

International Journal of Dermatology | January 15, 2021 | Volume: 60 | Issue: 8 | Pages: No page available

10.1111/ijd.15399 | PMID 33448344

Autoimmune progesterone dermatitis in the adolescent population

Pediatric Dermatology | December 27, 2020 | Volume: 38 | Issue: 2 | Pages: 380-384

10.1111/pde.14423 | PMID 33368681

AbstractBackground/ObjectiveAutoimmune progesterone dermatitis (APD) is a rare autoimmune hypersensitivity reaction that occurs cyclically at the peak of endogenous progesterone production during the menstrual cycle in women. No study characterizing APD in the adolescent population is found; it appears likely to be underdiagnosed and undertreated.MethodsA retrospective, single‐center, review of all adolescent and pediatric patients (<20 years old at onset) with documented diagnosis of APD.ResultsSeventeen adolescent APD patients were included (mean age at diagnosis: 14.4 ± 2 years, mean interval of 13.6 ± 11.1 months between symptom onset and diagnosis). Twelve patients presented with urticaria, two with fixed drug eruption. Erythema multiforme, eczema, and recurrent aphthous stomatitis were present in one patient each. Exposure to exogenous progestin was present in two patients prior to disease onset. Progesterone skin test was performed in six patients with positive results in two. Fourteen patients received antihistamines and/or a topical corticosteroid. Combined oral contraceptives (COCs) were given to eleven patients, in seven via continuous daily dosing. Gonadotropin‐releasing hormone agonist (GnRHa) was used in five, progesterone desensitization in four, omalizumab in two, and danazol in one patient.ConclusionsAdolescent APD is associated with a significant delay in diagnosis. The most common manifestation is urticaria. Exogenous exposure to progestins is uncommon in adolescent APD. Continuous COC, GnRHa, and progesterone desensitization have been used to control symptoms. Large, multicenter studies are required to better define, diagnose, and treat this under recognized condition among adolescent patients.
Oral vesicles and acral erythema: report of a cutaneous manifestation of COVID‐19

International Journal of Dermatology | July 25, 2020 | Volume: 59 | Issue: 9 | Pages: 1153-1154

10.1111/ijd.15047 | PMID 32710552